Closing of Private Placement

Gemina is targeting a series of significant multi-year licensing deals or partnerships with companies in the life sciences and medical device sectors to enable the delivery of next generation diagnostics with its unique, validated platform chemistry technology. One of the Company’s technologies, the Gemina Bridge, is a seminal development in the advancement of lateral flow assays (“LFA’s”) and has been evidenced to significantly reduce the amount of antibody required in diagnostic tests while retaining or enhancing test performance. This technology promises to deliver over 75% reduction in antibody requirements to one of the most cost intensive areas of LFA production and beyond. Integration of this technology inside partner products offers a compelling commercial opportunity for Gemina to engage with industry leaders to help deliver better diagnostics for patients and consumers.